FDA, EU Likely to Increase Use of Special Designations to Speed Approvals in 2013, Tufts Says

January 9, 2013
U.S. and EU regulators hope to increase the use of special designations, such as fast track, priority review and accelerated approval, to speed approvals of drugs for non-cancer diseases that are rare and/or life-threatening, according to a new Tufts report. Regulators want to approve these products at the same levels oncology drugs enjoyed between 2007 and 2011.
Drug Industry Daily